Skip to main content

Advertisement

SpringerLink
Log in

Prognostic impact of bone metastatic volume beyond vertebrae and pelvis in patients with metastatic hormone-sensitive prostate cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Although bone metastasis beyond the vertebrae and pelvis has been a key factor in prognostic models of metastatic hormone-sensitive prostate cancer (mHSPC), the clinical significance of it is still unclear. The present study evaluated the prognostic impact of the volume of bone metastasis beyond the vertebrae and pelvis on the outcomes of mHSPC and created an ideal risk classification based on it.

Methods

We retrospectively reviewed 197 patients with mHSPC who were treated with combined androgen blockade as the initial treatment between June 2003 and October 2019. We calculated the bone scan index (BSI), including the BSI beyond the vertebrae and pelvis (bBSI), using BONENAVI, and investigated the association between the BSI and the overall survival (OS) of mHSPC.

Results

According to the CHAARTED criteria, 91 and 106 patients were classified into the low- and high-volume groups, respectively. Of the 79 patients who did not have visceral metastasis in the high-volume group, those with a bBSI ≤ 0.27 (n = 16) showed a favorable OS, as did those in the low-volume group. The modified CHAARTED high-volume group (presence of visceral metastases or 4 bone lesions with a bBSI > 0.27) showed a significantly shorter OS than others, with a hazard ratio (HR) of 4.69 (p < 0.001), which was higher than that observed with the original CHAARTED criteria (HR = 4.33).

Conclusions

Our data suggested that considering the volume of bone metastasis beyond the vertebrae and pelvis may help to improve the accuracy of risk classification. Further large-scale prospective studies are needed to validate our findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Global Burden of Disease Cancer C, Fitzmaurice C, Akinyemiju TF et al (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 4(11):1553–1568

    Article  Google Scholar 

  2. Yap TA, Zivi A, Omlin A et al (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8(10):597–610

    Article  CAS  Google Scholar 

  3. Kelly SP, Anderson WF, Rosenberg PS et al (2018) Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 4(1):121–127

    Article  Google Scholar 

  4. Dall’Era MA, deVere-White R, Rodriguez D et al (2019) Changing incidence of metastatic prostate cancer by race and age, 1988–2015. Eur Urol Focus 5(6):1014–1021

    Article  Google Scholar 

  5. Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J Urol 168(1):9–12

    Article  Google Scholar 

  6. Laufer M, Denmeade SR, Sinibaldi VJ et al (2000) Complete androgen blockade for prostate cancer: what went wrong? J Urol 164(1):3–9

    Article  CAS  Google Scholar 

  7. Cattrini C, Castro E, Lozano R et al (2019) Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel) 11(9):1355

    Article  CAS  Google Scholar 

  8. Cornford P, van den Bergh RCN, Briers E et al (2020) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. https://doi.org/10.1016/j.eururo.2020.09.046

    Article  PubMed  PubMed Central  Google Scholar 

  9. Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321(7):419–424

    Article  CAS  Google Scholar 

  10. Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer. N Engl J Med 339(15):1036–1042

    Article  CAS  Google Scholar 

  11. Hussain M, Tangen CM, Berry DL et al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314–1325

    Article  CAS  Google Scholar 

  12. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373(8):737–746

    Article  CAS  Google Scholar 

  13. Poulsen MH, Rasmussen J, Edenbrandt L et al (2016) Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer. BJU Int 117(5):748–753

    Article  CAS  Google Scholar 

  14. Miyoshi Y, Yoneyama S, Kawahara T et al (2016) Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer 16:128

    Article  Google Scholar 

  15. Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195–202

    Article  CAS  Google Scholar 

  16. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159

    Article  Google Scholar 

  17. Koizumi M, Wagatsuma K, Miyaji N et al (2015) Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med 29(2):138–148

    Article  Google Scholar 

  18. Yamada Y, Sakamoto S, Rii J et al (2020) How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study. Prostate 80(5):432–440

    Article  Google Scholar 

  19. Akamatsu S, Kubota M, Uozumi R et al (2019) Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naive Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2(3):320–328

    Article  Google Scholar 

  20. Narita S, Hatakeyama S, Takahashi M et al (2020) Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan. Int J Clin Oncol 25(5):912–920

    Article  CAS  Google Scholar 

  21. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387

    Article  Google Scholar 

  22. Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458

    Article  CAS  Google Scholar 

  23. Shiota M, Namitome R, Kobayashi T et al (2019) Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer. Int J Urol 26(3):426–428

    Article  Google Scholar 

  24. Hatakeyama S, Narita S, Takahashi M et al (2020) Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study. Int J Urol 27(7):610–617

    Article  CAS  Google Scholar 

  25. Ulmert D, Kaboteh R, Fox JJ et al (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62(1):78–84

    Article  Google Scholar 

  26. Report of the task group on reference man (1979). Ann ICRP 3 (1–4):iii

  27. Fukagai T, Namiki TS, Carlile RG et al (2006) Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 97(6):1190–1193

    Article  CAS  Google Scholar 

  28. Bernard B, Muralidhar V, Chen YH et al (2017) Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123(9):1536–1544

    Article  CAS  Google Scholar 

  29. Fukasawa S, Suzuki H, Kawaguchi K et al (2018) Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Jpn J Clin Oncol 48(11):1012–1021

    Article  Google Scholar 

Download references

Acknowledgements

Statement of Ethics: The study design was approved by the Research Ethics Committee of our institution (No. 200256) and was conducted in accordance with the Declaration of Helsinki.

Author information

Authors and Affiliations

  1. Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan

    Kotaro Suzuki, Yasuyoshi Okamura, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata & Masato Fujisawa

Authors
  1. Kotaro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuyoshi Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuto Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoaki Terakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junya Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenichi Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuyuki Hinata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masato Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KS and TT designed the study. KS, YO and TH acquired and analyzed the data. KS and TT drafted the manuscript. JF, KH, NH and MF revised it critically for important intellectual content. All authors gave final approval of the version to be published.

Corresponding author

Correspondence to Kotaro Suzuki.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 146 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, K., Okamura, Y., Hara, T. et al. Prognostic impact of bone metastatic volume beyond vertebrae and pelvis in patients with metastatic hormone-sensitive prostate cancer. Int J Clin Oncol 26, 1533–1540 (2021). https://doi.org/10.1007/s10147-021-01931-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-01931-x

Keywords

Search

Navigation